388 related articles for article (PubMed ID: 27114197)
21. Effects of tadalafil treatment after bilateral nerve-sparing radical prostatectomy: quality of life, psychosocial outcomes, and treatment satisfaction results from a randomized, placebo-controlled phase IV study.
Patel HR; Ilo D; Shah N; Cuzin B; Chadwick D; Andrianne R; Henneges C; Barry J; Hell-Momeni K; Branicka J; Büttner H
BMC Urol; 2015 Apr; 15():31. PubMed ID: 25879460
[TBL] [Abstract][Full Text] [Related]
22. Impact of Baseline Total Testosterone Level on Successful Treatment of Sexual Dysfunction in Men Taking Once-Daily Tadalafil 5 mg for Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: An Integrated Analysis of Three Randomized Controlled Trials.
Mulhall JP; Brock GB; Glina S; Baygani S; Donatucci CF; Maggi M
J Sex Med; 2016 May; 13(5):843-51. PubMed ID: 27017071
[TBL] [Abstract][Full Text] [Related]
23. Tadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo- and tamsulosin-controlled, 12-week double-blind study.
Giuliano F; Oelke M; Jungwirth A; Hatzimouratidis K; Watts S; Cox D; Viktrup L
J Sex Med; 2013 Mar; 10(3):857-65. PubMed ID: 23346990
[TBL] [Abstract][Full Text] [Related]
24. Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a randomised placebo-controlled study (REACTT).
Montorsi F; Brock G; Stolzenburg JU; Mulhall J; Moncada I; Patel HR; Chevallier D; Krajka K; Henneges C; Dickson R; Büttner H
Eur Urol; 2014 Mar; 65(3):587-96. PubMed ID: 24169081
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of tadalafil in the treatment of Latin American men with erectile dysfunction: results of integrated analyses.
Rubio-Aurioles E; Casabé A; Torres LO; Quinzaños L; Glina S; Filimon I; Kopernicky V; Leñero E
J Sex Med; 2008 Aug; 5(8):1965-76. PubMed ID: 18466266
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of two dosing regimens of tadalafil and patterns of sexual activity in men with diabetes mellitus and erectile dysfunction: Scheduled use vs. on-demand regimen evaluation (SURE) study in 14 European countries.
Buvat J; van Ahlen H; Schmitt H; Chan M; Kuepfer C; Varanese L
J Sex Med; 2006 May; 3(3):512-20. PubMed ID: 16681477
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of tadalafil 20 mg on demand vs. tadalafil 5 mg once-a-day in the treatment of post-radiotherapy erectile dysfunction in prostate cancer men: a randomized phase II trial.
Ricardi U; Gontero P; Ciammella P; Badellino S; Valentino F; Munoz F; Guarneri A; Rondi N; Moretto F; Filippi AR; Ragona R; Tizzani A
J Sex Med; 2010 Aug; 7(8):2851-9. PubMed ID: 21711479
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of tadalafil in men with erectile dysfunction with a high prevalence of comorbid conditions: results from MOMENTUS: multiple observations in men with erectile dysfunction in National Tadalafil Study in the US.
Goldstein I; Kim E; Steers WD; Pryor JL; Wilde DW; Natanegara F; Wong DG; Ahuja S
J Sex Med; 2007 Jan; 4(1):166-175. PubMed ID: 17233782
[TBL] [Abstract][Full Text] [Related]
29. Daily Oral l-Arginine Plus Tadalafil in Diabetic Patients with Erectile Dysfunction: A Double-Blinded, Randomized, Controlled Clinical Trial.
El Taieb M; Hegazy E; Ibrahim A
J Sex Med; 2019 Sep; 16(9):1390-1397. PubMed ID: 31326304
[TBL] [Abstract][Full Text] [Related]
30. Comparative efficacy and safety of phosphodiesterase type 5 inhibitors for erectile dysfunction in diabetic men: a Bayesian network meta-analysis of randomized controlled trials.
Liao X; Qiu S; Bao Y; Wang W; Yang L; Wei Q
World J Urol; 2019 Jun; 37(6):1061-1074. PubMed ID: 30523399
[TBL] [Abstract][Full Text] [Related]
31. The role of initial success rates and other factors in determining reliability of outcomes of phosphodiesterase inhibitor therapy for erectile dysfunction: a pooled analysis of 17 placebo-controlled trials of tadalafil for use as needed.
Sontag A; Rosen RC; Litman HJ; Ni X; Araujo AB
J Sex Med; 2013 Feb; 10(2):541-50. PubMed ID: 22905853
[TBL] [Abstract][Full Text] [Related]
32. Effects of once-daily tadalafil on treatment satisfaction, psychosocial outcomes, spontaneous erections, and measures of endothelial function in men with erectile dysfunction but naive to phosphodiesterase type 5 inhibitors.
Porst H; Brock GB; Kula K; Moncada I; Montorsi F; Basson BR; Kinchen K; Aversa A
J Androl; 2012; 33(6):1305-22. PubMed ID: 22790642
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of Tadalafil Once-a-Day versus Tadalafil On-Demand in Patients with Erectile Dysfunction: A Systematic Review and Meta-Analyses.
Peng Z; Yang L; Dong Q; Wei Q; Liu L; Yang B
Urol Int; 2017; 99(3):343-352. PubMed ID: 28628914
[TBL] [Abstract][Full Text] [Related]
34. Low dose daily versus on-demand high dose tadalafil in diabetic patients with erectile and ejaculatory dysfunction.
Bolat MS; Cinar O; Akdeniz E; Aşcı R
Int J Impot Res; 2018 Jun; 30(3):102-107. PubMed ID: 29795527
[TBL] [Abstract][Full Text] [Related]
35. A comparison of the efficacy and tolerability of tadalafil 10 mg and 20 mg in Japanese patients with severe erectile dysfunction.
Marumo K; Imaoka T; Fujimoto K; Watts S; Stothard D; McGill J
J Sex Med; 2007 May; 4(3):745-752. PubMed ID: 17087800
[TBL] [Abstract][Full Text] [Related]
36. Role of Serum High-Sensitivity C-Reactive Protein as a Predictor of Therapeutic Response to Tadalafil in Patients With Erectile Dysfunction: A Prospective Observational Study.
Jamaluddin ; Bansal M; Srivastava GK; Gupta NP
J Sex Med; 2019 Dec; 16(12):1912-1921. PubMed ID: 31668733
[TBL] [Abstract][Full Text] [Related]
37. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
Eardley I; Montorsi F; Jackson G; Mirone V; Chan ML; Loughney K; Vail GM; Beardsworth A
BJU Int; 2007 Jul; 100(1):122-9. PubMed ID: 17552960
[TBL] [Abstract][Full Text] [Related]
38. The efficacy of tadalafil in clinical populations.
Lewis RW; Sadovsky R; Eardley I; O'Leary M; Seftel A; Wang WC; Shen W; Walker DJ; Wong DG; Ahuja S
J Sex Med; 2005 Jul; 2(4):517-31. PubMed ID: 16422847
[TBL] [Abstract][Full Text] [Related]
39. Predictors of tadalafil efficacy in men with erectile dysfunction: the SURE study comparing two dosing regimens.
Costa P; Buvat J; Holmes S; Weitckus S; Petto H; Hamidi K; Varanese L
J Sex Med; 2006 Nov; 3(6):1050-1058. PubMed ID: 17100938
[TBL] [Abstract][Full Text] [Related]
40. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study.
Egerdie RB; Auerbach S; Roehrborn CG; Costa P; Garza MS; Esler AL; Wong DG; Secrest RJ
J Sex Med; 2012 Jan; 9(1):271-81. PubMed ID: 21981682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
